Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

Carbogen Amcis (Shanghai) completed ANVISA Audit

A five-day inspection was concluded successfully with no critical and no major observations raised

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.

GenSci launches global innovation hub in Shanghai

The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges

Everest Medicines partners with Shanghai Pharma Subsidiary to accelerate the commercialization of XERAVA in Mainland China

Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China

WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services

It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China

CPHI & PMEC China sees surge in international attendance

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth

Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion

AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China

Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai

FDA grants orphan drug designation to MicuRx's MRX-5 for non-tuberculous mycobacteria infections

MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria